• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    卫

    卫材株式会社

    Eisai (company)
    企业
    2,787论文总数
    10.4万引用总数

    论文量&引用量时间轴

    机构学者

    论文(2787)

    年份
    起
    –
    止
    排序
    1Prescription Patterns of Hypnotics for Children and Adolescents in Japan: a Descriptive Epidemiologic Study Using a Claims Database
    Sachiko Tanaka-Mizuno, Kenichi Fujimoto,Kazuo Mishima,Yukinori Sakata, Motomu Suga, Hiroshi Ohashi,Naoki Kubota,Michinori Koebis,Toshiki Fukasawa,Kayoko Mizuno,Mika Ishii,Margaret Moline,

    STUDY OBJECTIVES:To investigate the prescription patterns for hypnotics among patients <18 years in Japan. METHODS:We conducted a descriptive epidemiologic study using a claims database in Japan. We included patients aged 0-17 years with first-time prescriptions for hypnotics between June 2021 and June 2023. Hypnotics were classified as melatonin, melatonin receptor agonists (MRAs), dual orexin receptor antagonists (DORAs), Z-drugs, and benzodiazepines. We described the types of hypnotics, dosages, prescription duration, comorbidities, and concomitant medications for overall and by age groups. RESULTS:The study included 21 145 patients; 1983 aged 0-6 years, 3901 aged 7-11 years, 6664 aged 12-14 years, and 8597 aged 15-17 years. The initial prescribed hypnotics were melatonin (33.9%), MRAs (30.9%), DORAs (18.8%), Z-drugs (10.1%), and benzodiazepines (6.3%). Melatonin was more likely to be prescribed to patients age 0-11 years, MRAs to those aged 0-17 years, and DORAs to patients ages 15-17 years. The most common mental health-related comorbidities were autism spectrum disorder (32.5%), depression (23.4%), attention-deficit hyperactivity disorder (19.8%), and anxiety disorder (18.2%). CONCLUSIONS:Melatonin was most frequently prescribed in children for a longer duration than other hypnotics, while MRAs were prescribed across all age groups and DORAs mainly to adolescents. These age-specific patterns suggest that the drug selection was conducted according to patient's age, since pediatric insomnia might be correlated with psychiatric disorders related to developmental stage. Future research should investigate the long-term effects of hypnotic prescriptions with consideration of comorbid conditions.

    2026Sleep(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Biomarkers, Cognitive Function, and Mortality in Centenarians
    Ryo Shikimoto,Takashi Sasaki,Yukiko Abe, Kenji Tai,Nobuyoshi Hirose,Hideyuki Okano,Yasumichi Arai

    Importance:Blood-based neural biomarkers linked to aging may provide insights into the biological end point of the human lifespan. However, the key biomarker associated with cognition and mortality in centenarians remains unclear. Objective:To investigate the associations between 3 neural biomarkers-amyloid-β42 and amyloid-β40 ratio (Aβ42/40), phosphorylated tau 181 (p-tau181), and neurofilament light chain (NfL)-and both cognitive function and all-cause mortality in centenarians. Design, Setting, and Participants:This population-based cohort study included Japanese centenarians aged 100 years or older who were enrolled between September 2000 and January 2021. Participants underwent baseline cognitive assessments and blood sampling and were followed up for 17 years for mortality. Data analysis was performed in February 2026. Exposures:Baseline plasma levels of Aβ42/40, p-tau181, and NfL measured using ultrasensitive immunoassays. Main Outcomes and Measures:Cognitive function at baseline, measured using the Mini-Mental State Examination (MMSE), and all-cause mortality. Results:Of 495 participants (398 [80.4%] women; mean [SD] age 104.1 [3.0] years), 419 completed a cognitive assessment (mean [SD] MMSE, 14.9 [6.9]). During 17 years of follow-up, 466 participants (95.5%) died. Lower Aβ42/40 (β = 0.99; 95% CI, 0.46 to 1.52) and higher NfL levels (β = -0.92; 95% CI, -1.62 to -0.23) were significantly associated with lower MMSE scores after adjusting for confounders. Higher NfL levels were also associated with increased mortality (hazard ratio, 1.36; 95% CI, 1.17 to 1.57), showing the greatest point estimate among the biomarkers, all of which were standardized and statistically significant (change in Akaike Information Criterion, likelihood ratio test, χ2 = 30.16; P < .001). Aβ42/40 and p-tau181 were not statistically significant after full adjustment. Conclusions and Relevance:In this cohort study of centenarians, higher plasma NfL levels were associated with lower cognitive function and increased all-cause mortality, whereas Aβ42/40 and p-tau181 showed no associations. These findings suggest that plasma NfL was associated with neurodegeneration in extreme aging. Further studies are needed to confirm its clinical utility before routine implementation.

    2026JAMA network open(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Effects of Lemborexant on Sleep Quality and Its Association with Morning Alertness: Post Hoc Analysis of Two Phase 3 Trials
    Masahiro Suzuki,Takuya Yoshiike,Atul Khullar, Yuki Kogo, Kanako Inabe,Michinori Koebis,Margaret Moline,Jocelyn Y Cheng,Dinesh Kumar, Kate Pinner,Kenichi Kuriyama

    Study Objectives This analysis was conducted to determine whether lemborexant (LEM) treatment affects ratings of patient-reported sleep quality and to identify subjective and objective parameters associated with improved subjective sleep quality. Methods This was a post hoc analysis of two global phase 3 trials (Study 303: 12-month, randomized, double-blind, placebo-controlled trial; Study 304: 1-month, randomized, double-blind, placebo-controlled, active-comparator trial) of LEM for patients with insomnia. A 9-point Likert scale (higher numbers indicating better quality) was used to assess subjective sleep quality (sQual). Subjective and objective sleep parameters were assessed by electronic sleep diaries and polysomnography, respectively. Spearman’s rank correlation analysis and stepwise regression analysis were performed to explore the associations between sleep parameters and sQual. Results The analyses included 949 patients from Study 303 and 743 patients from Study 304. LEM showed significantly larger increases from baseline in sQual than placebo in both studies (least square mean change: placebo 0.89, LEM5 1.17 (p<0.05); LEM10 1.21 (p<0.05) at Month 6 in Study 303, and placebo 0.93, LEM5 1.46 (p<0.001), LEM10 1.35 (p<0.05) at Month 1 in Study 304). Of subjective sleep parameters, changes in morning alertness showed the strongest association with changes in sQual. The changes in subjective total sleep time and wake after sleep onset were moderately correlated with sQual positively and negatively, respectively. These findings were further confirmed using stepwise regression analyses. Conclusions LEM improved ratings of sQual more than placebo. To improve self-reported sleep quality, lemborexant treatment should focus on improving morning alertness. Clinical Trial Registration Study 303 (ClinicalTrials.gov NCT02952820): Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2). https://clinicaltrials.gov/study/NCT02952820, Study 304 (ClinicalTrials.gov NCT02783729): Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older with Insomnia Disorder (SUNRISE 1). https://clinicaltrials.gov/study/NCT02783729

    2026Sleep medicine X(2026)
    引用
    AI阅读
    加入学术空间
    4First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck
    Nobuaki Matsubara,Ken Saijo,Yasushi Shimizu,Susumu Okano,Kenji Nakano,Naoki Nishio,Tomoyuki Otsuka,Hirofumi Kuno,Takuma Miura, Tomoki Kubota,Hiroki Ikezawa, Yuko Umetsu,

    The dose escalation part of the first-in-human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose (RP2D) of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck (SCCHN) and urothelial carcinoma (UC). Patients ≥ 20 years of age with previously treated SCCHN/UC were treated at the RP2D. The primary objective was to characterize tolerability/safety. Secondary objectives included preliminary efficacy (including objective response rate [ORR], progression-free survival [PFS], and duration of response [DOR] by investigator per Response Evaluation Criteria In Solid Tumors version 1.1 [RECIST v1.1] and overall survival [OS]). Treatment-emergent adverse events (TEAEs) were recorded. In patients with SCCHN, tissue biomarker analyses were performed. Kaplan-Meier method was used to estimate PFS, DOR, and OS. The Greenwood formula and log-log transformation were used to estimate 95% CIs. Eight patients (SCCHN, n = 2; UC, n = 6) were treated with the RP2D; 10 additional patients (SCCHN, n = 7; UC, n = 3) were treated at a reduced dose (410 μg/m2 Q3W). All patients had ≥ 1 TEAE; 66.7% had serious TEAEs. Patients with UC treated at the RP2D had an ORR of 66.7%; no other responses were observed. Median PFS/OS in patients with SCCHN treated at 480 μg/m2 were 2.8/7.7 months and at 410 μg/m2 were 3.5/5.0 months. Median PFS/OS in patients with UC treated at 480 μg/m2 were 6.6/10.7 months and at 410 μg/m2 were 2.6/11.9 months. Biomarker analyses indicated tumor microenvironment amelioration. Further evaluation is needed to optimize efficacy and safety of E7130 in patients with SCCHN and UC. Trial Registration: ClinicalTrials.gov identifier: NCT03444701.

    2026Cancer science(2026)
    引用
    AI阅读
    加入学术空间
    5Heart Rate Variability-Based Machine Learning Model for Predicting Convulsions in Non-Human Primates: Validation with a Human Convulsant Compound
    Motohiro Shiotani,Hiroshi Mizuno, Yusaku Matsushita,Takashi Yoshinaga,Shoji Asakura

    [Background] Drug-induced convulsions represent a significant toxicological risk in drug development, requiring reliable biomarkers that can detect early signs of convulsive activity. We have experienced that our compound induced a convulsion in a clinical trial (”Compound X"; sodium channel blocker). For Compound X, we conducted an electroencephalogram (EEG) study in non-human primates (NHPs) but found no EEG abnormalities at dose levels lower than convulsive dose. Then, we co-developed a machine learning-based convulsion prediction model using heart rate variability (HRV) data from NHPs, trained on both convulsant and non-convulsant compounds (Kuga et al., 2024). This model calculates a “convulsive index" by identifying deviations in autonomic nervous system activity. Recently, we refined the model to reduce false positives caused by non-convulsant compounds that influence HRV. [Objectives] Here, we introduced an evaluation result of Compound X with the refined model and discussed the usefulness of our model for the preclinical convulsion assessment. [Methods] Telemetry-implanted male NHPs (n = 4) received oral doses of Compound X (0 [vehicle], 3, 10, and 30 mg/kg) in a Latin square design. Heart rate data were collected for approximately 6 h post-dose and analyzed using our refined model to calculate the convulsive index. For the 10 and 30 mg/kg doses, approaching convulsion-inducing levels in NHPs, retrospective toxicokinetic analysis was conducted to compare the Cmax in NHPs with the blood concentration at which convulsions occurred in humans. [Results] No convulsions were observed in any animal. However, the mean convulsive index increased in a dose-dependent manner. Apparently higher index values were observed in 1 animal at 10 mg/kg and 2 animals at 30 mg/kg (approximately 8-fold higher than the individual vehicle-treated values). The Cmax values in these 3 animals were close to the blood concentration at convulsion occurrence in humans (approximately 0.5 to 2 times that in humans). [Conclusions] These findings suggest that our HRV-based model can sensitively detect autonomic changes associated with convulsion risk prior to convulsion occurrence. The convulsive index may serve as a valuable preclinical biomarker, and future applications in human studies could support proactive safety assessments and the prevention of unexpected convulsions.

    2026JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2787 篇论文

    合作机构(100)

    Eisai Inc.合作论文 466
    东京大学合作论文 102
    National Cancer Center Hospital East合作论文 81
    近畿大学合作论文 50
    默克制药公司合作论文 49
    庆应义塾大学合作论文 47
    京都大学合作论文 46
    KAN Research Institute合作论文 34
    名古屋大学合作论文 28
    筑波大学合作论文 27

    机构统计